Drug-Drug Interactions, Dosing, Formulations, and Other Pharmacologic Issues in HIV Treatment (On-Demand)

Assessment of Needs

Clinicians managing patients with HIV require updated education on pharmacologic considerations that impact treatment safety and efficacy. There is a clear need for enhanced understanding of drug-drug interactions, metabolic and clearance pathways, and the interpretation of laboratory results affected by specific antiretroviral agents. Additionally, practitioners must be aware of alternative antiretroviral formulations and dosing strategies for those who are unable to take oral tablets. This webinar offers practical strategies to improve clinical decision-making and ensure optimal patient outcomes in complex treatment scenarios, and provides an overview of major drug interactions for current antiretroviral therapy drugs such as cabotegravir, lenacapavir, and doravirine.

Learning Objectives

 On completion of this activity, learners will be able to:

• Identify common metabolic and clearance pathways involved in antiretroviral drug metabolism and how co-administered medications may alter these pathways

• Recognize medications that affect serum creatinine levels without indicating true renal dysfunction and interpret these laboratory findings appropriately

• Evaluate potential drug-drug interactions in patients receiving complex antiretroviral therapy and apply strategies to minimize adverse effects or treatment failure

• Integrate pharmacologic principles into individualized HIV treatment plans to optimize safety, adherence, and virologic suppression

Registration

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Please note: if you have already participated in the live webinar and have received CME credits, you will not receive additional credits from this activity.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities. 

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA has identified and mitigated ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. All relevant financial relationships with ineligible companies have been mitigated among the planners and the presenter. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Presenter

Dr Burger reported consulting or advisor fees to his institution from Merck Sharp & Dohme, and grants/grants pending to his institution from Merck Sharp & Dohme, Gilead Sciences, Inc., and ViiV Healthcare. (Updated October 12, 2025)

Moderator

Dr Dong reported no financial relationships with ineligible companies. (Updated September 23, 2025)

COW Board

The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/